Fig. 2From: Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritisSecond and third etanercept treatment course, therapy survival, and reasons for discontinuation (single categories (ineffectiveness, adverse events, other reasons, unknown) do not add up to the rate of other reasons than inactive disease by the possibility of multiple responses)Back to article page